^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 overexpression + TMB-H

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, TMB | Tumor Mutational Burden
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    2years
    A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. (PubMed, Front Cell Dev Biol)
    A total of 15 potential small molecule compounds (such as depactin, physostigmine, and phenacetin) were identified. FRGPI is a promising gene panel for predicting the prognosis, immune characteristics, temozolomide sensitivity, and ICI response in patients with glioma.
    Journal • Checkpoint inhibition • Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD4 (CD4 Molecule) • HMOX1 (Heme Oxygenase 1) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • PD-L1 overexpression + TMB-H
    |
    temozolomide